Allison Whitten

Nashville

Assistant Editor at DDN

Assistant Editor @DrugDiscovNews. PhD @VanderbiltU. Past @AAASMassMedia @DiscoverMag @QuantaMagazine. Fan of @UMichFootball.

Articles

Epigenetic editing expands the reach of gene therapy

3 weeks ago | drugdiscoverynews.com | Allison Whitten

Rather than permanently cutting DNA, this new kind of gene therapy instead aims to regulate gene expression using epigenetic mechanisms. Credit: iStock.com/OseloteRather than permanently cutting DNA, this new kind of gene therapy instead aims to regulate gene expression using epigenetic mechanisms. | 6 min readAllison Whitten, PhDRegister for free to listen to this articleGene editing therapies are designed to be a one-and-done fix that cure a genetic disease and last a lifetime.
To fight HIV, antibodies boost the immune system

1 month ago | drugdiscoverynews.com | Allison Whitten

HIV is incurable because it hides in latently infected cells. Researchers are hoping to change that — and prevent new infections — with the use of antibodies. HIV is incurable because it hides in latently infected cells. Researchers are hoping to change that — and prevent new infections — with the use of antibodies. | 8 min readAllison Whitten, PhDRegister for free to listen to this articleOnce the human immunodeficiency virus (HIV) enters a cell, there is no going back.
A new Parkinson’s disease treatment that adapts to the brain

1 month ago | drugdiscoverynews.com | Allison Whitten

The hallmark symptoms of Parkinson’s disease — shaky hands, muscle stiffness, slowed movements, and difficulty with balance — signify underlying irreversible damage to dopaminergic neurons in the brain. “Unfortunately, there is no cure for Parkinson's, and there are no disease-modifying therapies — meaning our treatments are only symptomatic,” said Suneil Kalia, a neurosurgeon and neuroscientist at the University of Toronto.
The biggest barriers in drug development today

2 months ago | drugdiscoverynews.com | Allison Whitten

We asked industry leaders and academic researchers in the fields of hematology, pain, HIV, and neurology what they see as the major obstacles holding back the development of new drugs today. What do you see as the biggest barriers in drug development today?
Giving promising drug compounds a second chance

2 months ago | drugdiscoverynews.com | Allison Whitten

After two decades working in leadership positions at big pharmaceutical companies like AstraZeneca and Novartis, immunologist and emergency physician Volkan Manga wanted to go in a new direction. He realized that as he watched some drugs pass through clinical trials and reach real patients, many more drugs with great potential sat by the wayside.
2025 Breakthrough Prizes in Life Sciences announced | Drug Discovery News

2 months ago | drugdiscoverynews.com | Allison Whitten |Stephanie DeMarco |Dika Ojiakor

Advances in GLP-1 research for diabetes and obesity, multiple sclerosis discoveries, and DNA editing are awarded in this year’s prestigious prize.
Antibiotics disrupt the beneficial mucus barrier lining the gut

Mar 24, 2025 | drugdiscoverynews.com | Allison Whitten

Antibiotics target bacteria, but new work in mice shows they also harm the mucus layer that protects the intestinal lining from microbes. Antibiotics target bacteria, but new work in mice shows they also harm the mucus layer that protects the intestinal lining from microbes.
What’s next for the first non-opioid pain drug in 20 years

Mar 18, 2025 | drugdiscoverynews.com | Allison Whitten

Opioids provide extremely quick pain relief — within a single minute when injected directly into the bloodstream. But they come with a high cost: Opioids are highly addictive due to their direct activation of opioid receptors involved in the brain’s reward circuitry. In 2022 alone, more than 80,000 Americans died from an opioid overdose (1). Novel non-opioid pain medications are urgently needed, but none had been approved in more than 20 years.
A dual-threat cancer drug takes aim at resistance mechanisms

Mar 17, 2025 | drugdiscoverynews.com | Allison Whitten

Judy Sebolt-Leopold and her team at MEKanistic Therapeutics developed a single molecule targeting two kinase enzymes that drive resistance to cancer therapies. Judy Sebolt-Leopold and her team at MEKanistic Therapeutics developed a single molecule targeting two kinase enzymes that drive resistance to cancer therapies.
Illuminating the full side effect profile of GLP-1 drugs

Mar 10, 2025 | drugdiscoverynews.com | Allison Whitten

When Lili Zarghami walked out of her doctor’s office with a free box of Mounjaro — a glucagon-like peptide-1 (GLP-1) agonist from Eli Lilly — she felt hopeful that the drug might help her shed extra pounds she had gained related to having polycystic ovary syndrome (PCOS). She injected herself with the first dose on a Saturday afternoon, and by Sunday, her appetite — and any thoughts about food whatsoever — had vanished. “There was literally no desire to eat anything,” said Zarghami.